期刊
HUMAN MUTATION
卷 37, 期 6, 页码 524-531出版社
WILEY
DOI: 10.1002/humu.22977
关键词
thoracic aortic aneurysm; Marfan syndrome; MFS; Loeys-Dietz syndrome; LDS; TGF-beta signaling; FBN1; TGFBR1; TGFBR2; SMAD2; SMAD3; TGFB2; TGFB3; SKI
资金
- University of Antwerp (Lanceringsproject)
- Fund for Scientific Research, Flanders (FWO, Belgium) [G.0221.12]
- Dutch Heart Foundation [2013T093]
- European Research Council [ERC- StG-2012-30972-BRAVE]
- Fondation Leducq (MIBAVA) [Leducq 12CVD03]
Marfan syndrome (MFS) is a rare, autosomal-dominant, multisystem disorder, presenting with skeletal, ocular, skin, and cardiovascular symptoms. Significant clinical overlap with other systemic connective tissue diseases, including Loeys-Dietz syndrome (LDS), Shprintzen-Goldberg syndrome (SGS), and the MASS phenotype, has been documented. In MFS and LDS, the cardiovascular manifestations account for the major cause of patient morbidity and mortality, rendering them the main target for therapeutic intervention. Over the past decades, gene identification studies confidently linked the aforementioned syndromes, as well as nonsyndromic aneurysmal disease, to genetic defects in proteins related to the transforming growth factor (TGF)-beta pathway, greatly expanding our knowledge on the disease mechanisms and providing us with novel therapeutic targets. As a result, the focus of the developing pharmacological treatment strategies is shifting from hemodynamic stress management to TGF-beta antagonism. In this review, we discuss the insights that have been gained in the molecular biology of MFS and related disorders over the past 25 years. (C) 2016 Wiley Periodicals, Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据